Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Oncolytics Biotech Inc
T.ONC
Alternate Symbol(s):
ONCY
Healthcare
Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and...
adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:ONC)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(5618)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Sep 15, 2024 6:06pm
RE:Pelareorep in 3rd line HR+/HER2 negative breast cancer
While the ASCO Meeting Abstract from the 2022 ASCO Annual Meeting has cited that the average cost for the first year of HR+/HER2 negative was US$192,367 per patient, it also referenced that
...more
(5618)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Sep 15, 2024 4:46pm
RE:Pelareorep in 3rd line HR+/HER2 negative breast cancer
this patient group would translate into approximately US$10.56 Billion in annual sales for pelareorep or a significant percentage of this gross sales value
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource
posted Sep 19, 2024 9:00am by
Northstar Gold Corp.
-
|
The MOU grants Hunan Nonferrous the opportunity to explore and develop a near-surface NI43-101 gold mineral resource at Northstar’s 100%-owned Miller Copper-Gold Property, located 18 kilometers southeast of Kirkland Lake, Ontario. This will be achieved by diamond drilling up to 10,000 meters, allowing Hunan Nonferrous to earn a negotiated interest in the resultant NI43-101 gold resource. ...read more
(5618)
•••
Noteable
X
View Profile
View Bullboard History
Post by
Noteable
on Sep 15, 2024 4:43pm
Pelareorep in 3rd line HR+/HER2 negative breast cancer
ONCY should easily be able to enroll 180-200 patients for its Phase2b -> Phase3 -> Confirmatory metastatic breast cancer patients since there is a significant unmet need for patients who will
...more
(290)
•••
inthno
X
View Profile
View Bullboard History
Comment by
inthno
on Sep 15, 2024 4:40pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY's pelareorep activates TiLs (CD8+ Dendritic Cells)
I certainly hope that you are right Note as I do not consider 3rd line patients with a compromised immune system the same patient population that was in the mbc 213 trial. As for the 55k patients
...more
(5618)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Sep 15, 2024 3:19pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY's pelareorep activates TiLs (CD8+ Dendritic Cells)
The long view is eventually moving pelareorep into first line therapy in combination with a variation of immune checkpoint inhibitors +/- bispecifics +/- ADCs +/- small molecule inhibitors +/- CAR-T
...more
(5618)
•••
Noteable
X
View Profile
View Bullboard History
Post by
Noteable
on Sep 15, 2024 2:45pm
ONCY's pelareorep in 3rd line HR+/HER2 negative breast cance
ONCY should easily be able to enroll 180-200 patients for its Phase2b -> Phase3 -> Confirmatory metastatic breast cancer patients since there is a significant unmet need for patients who will
...more
(5618)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Sep 15, 2024 1:45pm
RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals
An ASCO Meeting Abstract from the 2022 ASCO Annual Meeting has cited that the average cost for the first year of HR+/HER2 negative was US$192,367 per patient. With ONCY stating that
...more
(5618)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Sep 15, 2024 1:42pm
RE:RE:Breast cancer treatment: perspectives on the oncolytic virus
In 2022, there were 2.3 million women diagnosed with breast cancer and 670 000 deaths globally. https://www.who.int/news-room/fact-sheets/detail/breast-cancer In 2024 approximately 310,720
...more
(5618)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Sep 15, 2024 10:11am
RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY's pelareorep activates TiLs (CD8+ Dendritic Cells)
The long view is eventually moving pelareorep into first line therapy in combination with a variation of immune checkpoint inhibitors +/- bispecifics +/- ADCs +/- small molecule inhibitors
...more
(5618)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Sep 15, 2024 10:05am
RE:RE:RE:RE:RE:RE:RE:RE:ONCY's pelareorep activates TiLs (CD8+ Dendritic Cells)
Don't lose sight of the fact that 55,000 3rd line mBC patients at a cost of approximately $US 100k per patient treatment equals to $US 5.5 Billion of pelareorep sales annually.
(5618)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Sep 15, 2024 10:00am
RE:RE:RE:RE:RE:RE:RE:RE:ONCY's pelareorep activates TiLs (CD8+ Dendritic Cells)
And no ... ONCY will NOT be dealing with a different patient population. ONCY will be dealing with the same patient population who have failed a 2nd line breast cancer therapy, whether it was CDK4,6
...more
(5618)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Sep 15, 2024 9:46am
RE:RE:RE:RE:RE:RE:RE:RE:ONCY's pelareorep activates TiLs (CD8+ Dendritic Cells)
As I've already stated It should be easy to enroll 180-200 patients because (1) patients who have progressed from Enhertu will already have been identified as those who are eligible for 3rd line
...more
(290)
•••
inthno
X
View Profile
View Bullboard History
Comment by
inthno
on Sep 14, 2024 11:06pm
RE:RE:RE:RE:RE:RE:RE:ONCY's pelareorep activates TiLs (CD8+ Dendritic Cells)
I am not sure how easily it will be able to enroll that many patients as there are a lot of trials out there but with the help of a hopeful partner it will be much easier as it will be promoted much
...more
(5618)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Sep 14, 2024 9:12pm
RE:RE:RE:RE:RE:RE:ONCY's pelareorep activates TiLs (CD8+ Dendritic Cells)
Should read: ONCY should be able to easily enroll 180-200 global patients given the unmet medical need in 3rd line mBC that pelareorep + paclitaxel is seeking to address. ONCY is looking to enroll
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
EnviroGold Global Announces Appointment of Chief Operating Officer
Mining Player Sells Off Promising Project for Millions – Here's Where the Cash is Headed